A large genomic characterization study found specific somatic copy number alterations to have prognostic implications for metastasis, resistance, and novel therapeutic approaches in metastatic triple-negative breast cancer.
NEW YORK (Reuters Health) - Omitting radiation after lumpectomy for pure ductal carcinoma in situ (DCIS) does not improve the chance of breast preservation in case of local recurrence, researchers from Canada have observed.
A recent comparative effectiveness study examined long-term survival outcomes for patients with multiple stages of breast cancer after undergoing either mastectomy or breast-conserving surgery, published in the Journal of Global Oncology (August 2017;3:304-313).
IBM’s Watson for Oncology, a computer that helps oncologists make treatment decisions for individual patients, made the same recommendations 90% of the time as a team of specialist oncologists, according to a new study presented on Friday, December 9, at the San Antonio Breast Cancer Symposium.
Use of the 21-gene recurrence score (RS) assay is helping clinicians and patients decide which treatments are best for them, according to a large-scale survey of more than 3000 women treated for breast cancer.
Adjuvant endocrine therapy with tamoxifen or aromatase inhibitors may reduce the risk for contralateral breast cancer (CBC) in women with invasive breast cancer according to results from a study published in JAMA Oncology.
Response-guided neoadjuvant chemotherapy (RG-NACT) is more cost effective than conventional NACT for estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, according to a study published in BMC Cancer.